Pfizer Inc. (PFE) posted stronger-than-expected earnings on Tuesday, but it wasn’t enough to dispel the cloud hanging over the once-heroic drugmaker.
Long lauded for its central role in the global Covid-19 response, the pharmaceutical giant now finds itself under intense investor scrutiny. While shares climbed nearly 4% to close at $24 following the report, they remain down roughly 13% in 2025 and recently touched their lowest level since July 2012.
The New York-based company reported adjusted diluted earnings of $0.92 per share for the first quarter, comfortably beating the $0.67 per-share consensus estimate. Revenue, however, came in slightly short at $13.71 billion, missing Wall Street’s $13.92 billion target. Cost controls, including a 12% year-over-year drop in adjusted operating expenses, helped buoy profitability even as top-line growth faltered.
Dividend Strength and Junk Bond Comparisons Raise Eyebrows
Pfizer’s share price decline has created an unexpected point of attraction: its dividend yield, now hovering at 7.4%. That level rivals the returns of many high-yield—or "junk"—bond funds, including the iShares iBoxx $ High Yield Corporate Bond ETF (HYG), which currently yields around 7.5%. For investors seeking income in a volatile market, Pfizer’s consistent payouts may present a more stable alternative to speculative debt instruments.
Pfizer’s dividend history lends credibility to the yield’s sustainability. The company hasn’t missed a quarterly payment in more than 80 years and has raised its dividend annually for a decade. Its current annual payout of $1.72 represents just under 60% of projected 2025 earnings—a higher ratio than the healthcare sector average, but still considered manageable.
Still, risks abound. Pfizer faces a looming wave of patent expirations expected to erode more than $15 billion in sales by decade’s end. Its attempt to counterbalance that with obesity treatments has stumbled; earlier this month, Pfizer scrapped its experimental oral drug danuglipron over liver safety concerns. CEO Albert Bourla defended the move, calling it “the right decision for the company.”
Tariff Uncertainty Looms Over Pharma Sector
An added layer of complexity for Pfizer and the broader pharmaceutical industry comes from the threat of tariffs under a potential second Trump administration. Bourla acknowledged national security concerns tied to drug imports but argued tariffs would be the wrong tool. “No country wants to have critical medicines produced in countries where tensions are high or can escalate,” he said on Tuesday’s earnings call. He emphasized tax incentives—not tariffs—as a better path to encouraging domestic investment.
CFO David Denton said Pfizer is already absorbing a $150 million hit from current tariffs and warned of more to come. The company is evaluating contingency plans, including shifting production of certain ingredients and finished products to U.S. facilities.
Despite the political headwinds, Pfizer reaffirmed its 2025 financial guidance, forecasting revenue between $61 billion and $64 billion and adjusted diluted earnings of $2.80 to $3.00 per share. Notably, the guidance excludes any tariff-related impacts.
Outlook: Cautious Optimism Hinges on M&A and Execution
To rebuild its pipeline and offset lost Covid-19 revenue, Pfizer is turning to acquisitions. Bourla said the company expects to complete two to three deals this year totaling up to $15 billion. These moves are part of a broader strategy to reinvent the business after its pandemic windfall.
Cost cuts will also play a central role. Pfizer now expects to achieve $7.7 billion in savings by the end of 2027, up from previous forecasts, through a mix of R&D reorganization, manufacturing optimization, and streamlined operations.
For now, Wall Street remains wary. The company’s recovery hinges on successful execution of its M&A strategy, insulation from disruptive policy shifts, and the ability to bring new drugs to market before key patents expire. With its stock near historic lows and a dividend that rivals high-yield debt, Pfizer offers an unusual combination of risk and reward in a turbulent healthcare landscape.
The New York-based company reported adjusted diluted earnings of $0.92 per share for the first quarter, comfortably beating the $0.67 per-share consensus estimate. Revenue, however, came in slightly short at $13.71 billion, missing Wall Street’s $13.92 billion target. Cost controls, including a 12% year-over-year drop in adjusted operating expenses, helped buoy profitability even as top-line growth faltered.
Dividend Strength and Junk Bond Comparisons Raise Eyebrows
Pfizer’s share price decline has created an unexpected point of attraction: its dividend yield, now hovering at 7.4%. That level rivals the returns of many high-yield—or "junk"—bond funds, including the iShares iBoxx $ High Yield Corporate Bond ETF (HYG), which currently yields around 7.5%. For investors seeking income in a volatile market, Pfizer’s consistent payouts may present a more stable alternative to speculative debt instruments.
Pfizer’s dividend history lends credibility to the yield’s sustainability. The company hasn’t missed a quarterly payment in more than 80 years and has raised its dividend annually for a decade. Its current annual payout of $1.72 represents just under 60% of projected 2025 earnings—a higher ratio than the healthcare sector average, but still considered manageable.
Still, risks abound. Pfizer faces a looming wave of patent expirations expected to erode more than $15 billion in sales by decade’s end. Its attempt to counterbalance that with obesity treatments has stumbled; earlier this month, Pfizer scrapped its experimental oral drug danuglipron over liver safety concerns. CEO Albert Bourla defended the move, calling it “the right decision for the company.”
Tariff Uncertainty Looms Over Pharma Sector
An added layer of complexity for Pfizer and the broader pharmaceutical industry comes from the threat of tariffs under a potential second Trump administration. Bourla acknowledged national security concerns tied to drug imports but argued tariffs would be the wrong tool. “No country wants to have critical medicines produced in countries where tensions are high or can escalate,” he said on Tuesday’s earnings call. He emphasized tax incentives—not tariffs—as a better path to encouraging domestic investment.
CFO David Denton said Pfizer is already absorbing a $150 million hit from current tariffs and warned of more to come. The company is evaluating contingency plans, including shifting production of certain ingredients and finished products to U.S. facilities.
Despite the political headwinds, Pfizer reaffirmed its 2025 financial guidance, forecasting revenue between $61 billion and $64 billion and adjusted diluted earnings of $2.80 to $3.00 per share. Notably, the guidance excludes any tariff-related impacts.
Outlook: Cautious Optimism Hinges on M&A and Execution
To rebuild its pipeline and offset lost Covid-19 revenue, Pfizer is turning to acquisitions. Bourla said the company expects to complete two to three deals this year totaling up to $15 billion. These moves are part of a broader strategy to reinvent the business after its pandemic windfall.
Cost cuts will also play a central role. Pfizer now expects to achieve $7.7 billion in savings by the end of 2027, up from previous forecasts, through a mix of R&D reorganization, manufacturing optimization, and streamlined operations.
For now, Wall Street remains wary. The company’s recovery hinges on successful execution of its M&A strategy, insulation from disruptive policy shifts, and the ability to bring new drugs to market before key patents expire. With its stock near historic lows and a dividend that rivals high-yield debt, Pfizer offers an unusual combination of risk and reward in a turbulent healthcare landscape.
Considering a $1,000 investment in these companies?
Our team at Stock Investor carefully curated a list of top stocks with the potential for significant returns, suitable for beginners and seasoned investors alike who are eager to learn a trade and unearth the best stocks to buy. Though not featured in this article, these selected stocks could be game-changers in the future.For those seeking dynamic trading experiences, consider joining our Swing Trade Alerts, Option Income Alert, or our Trading Room. Take advantage of our special offer today, starting at just $1 in the first month.
Unlock the secrets of Smart Money
Explore how billionaires and institutions are influencing the market. Follow their every move with DarkOption Flow and stay updated on essential market insights. Begin your journey to informed investing today!
Education
And if you're a fan of Invest opedia, you'll appreciate what we offer at SharperTrades even more. Explore our comprehensive option trading course and technical trading course, where you can learn trading, analyze stocks, delve into chart patterns for stocks, and gain invaluable insights for making the best company investments.
Unlock Your Stock Market Edge with SharperTrades. Dive into powerful trading tools, learn a trade, and receive expert guidance. Stay up-to-date with regular market updates. Learn trading, basics of investing, and how to pick the best stocks to buy. Whether you're a beginner or seasoned investor and trader, we've got you covered. Get started for free, today!